← Leaderboards
Valder R Arruda
Children'S Hospital Of Philadelphia
$13,574,051
Attributed
$13,999,301
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2005–22$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$18,244,446 · 10
By mechanism
P01$7,824,542 · 3
U54$7,418,936 · 3
R01$2,710,664 · 3
K01$290,304 · 1
Top collaborators
- Michael C. Milone2 shared
Most similar at Children'S Hospital Of Philadelphia
Same institution · by research overlap
- Andrew J Gow$5,320,150
- Amy R. Brooks-Kayal$9,632,011
- Michael B Robinson$24,822,084
- Garrett M Brodeur$23,136,915
- Marc Yudkoff$3,459,271
Others in their field
Top investigators on “Hemophilia A”
- Carol H Miao · Seattle Children'S Hospital$27,105,989
- Mark A Kay · Stanford University$24,062,703
- Roland W. Herzog · Indiana University Indianapolis$22,911,482
- Timothy Charles Nichols · University Of North Carolina Chapel Hill$19,506,050
- John S. Lollar · Emory University$17,412,316
- Mortimer Poncz · University Of Pennsylvania$14,969,626
Research focus
Hemophilia AInhibitor/AntagonistBaseLinkSeriesF8 GeneMorbidity - Disease RateGenesHemophilia BCanis FamiliarisBloodHemorrhageSiteVariantSafetyProteinsImmune ResponseMolecularMutationAffectNovel TherapeuticsPreventGene TherapyLaboratories
Grant awards (37)
Biochemistry of Intrinsic Xase$732,776
P01 · FY2022 · HL · contact PI
Characterization of the Functional Repertoire and Ontogeny of FVIII Humoral Response Across Species: Project 1$346,158
U54 · FY2022 · HL · contact PI
Skills Development$276,804
U54 · FY2022 · HL · contact PI
Molecular and cellular mechanisms of the FVIII immune response$1,396,051
U54 · FY2021 · HL · contact PI
Immune tolerance induction by AAV-FVIII gene therapy for canine hemophilia A with inhibitors$746,236
R01 · FY2021 · HL · contact PI
Biochemistry of Intrinsic Xase$732,776
P01 · FY2021 · HL · contact PI
Characterization of the Functional Repertoire and Ontogeny of FVIII Humoral Response Across Species: Project 1$349,314
U54 · FY2021 · HL · contact PI
Skills Development$276,797
U54 · FY2021 · HL · contact PI
Molecular and cellular mechanisms of the FVIII immune response$1,390,984
U54 · FY2020 · HL · contact PI
Biochemistry of Intrinsic Xase$495,230
P01 · FY2020 · HL · contact PI
Characterization of the Functional Repertoire and Ontogeny of FVIII Humoral Response Across Species: Project 1$352,168
U54 · FY2020 · HL · contact PI
Skills Development$276,612
U54 · FY2020 · HL · contact PI
Biochemistry of Intrinsic Xase$426,871
P01 · FY2019 · HL · contact PI
Characterization of the Functional Repertoire and Ontogeny of FVIII Humoral Response Across Species: Project 1$355,139
U54 · FY2019 · HL · contact PI
Skills Development$276,613
U54 · FY2019 · HL · contact PI
Molecular and cellular mechanisms of the FVIII immune response$1,458,110
U54 · FY2018 · HL · contact PI
Biochemistry of Intrinsic Xase$430,000
P01 · FY2018 · HL · contact PI
Engineering cellular immunotherapy to modulate immune responses in hemophilia$416,250
R01 · FY2018 · HL · contact PI
Characterization of the Functional Repertoire and Ontogeny of FVIII Humoral Response Across Species: Project 1$381,131
U54 · FY2018 · HL · contact PI
Skills Development$283,055
U54 · FY2018 · HL · contact PI
Engineering cellular immunotherapy to modulate immune responses in hemophilia$434,250
R01 · FY2017 · HL · contact PI
Novel Therapy for Hemophilia B Using AAV-FIX Variants$511,160
P01 · FY2015 · HL · contact PI
Novel Therapy for Hemophilia B Using AAV-FIX Variants$507,191
P01 · FY2014 · HL · contact PI
Novel Therapy for Hemophilia B Using AAV-FIX Variants$493,617
P01 · FY2013 · HL · contact PI
Novel Therapy for Hemophilia B Using AAV-FIX Variants$532,996
P01 · FY2012 · HL · contact PI
Novel Therapy for Hemophilia B Using AAV-FIX Variants$384,370
P01 · FY2011 · HL · contact PI
Intravascular Delivery of AAV to Skeletal Muscle$558,266
P01 · FY2009 · HL · contact PI
Intravascular Delivery of AAV to Skeletal Muscle$531,040
P01 · FY2008 · HL · contact PI
AAV2-F.IX Hepatic Gene Transfer under Immunomodulation$371,214
R01 · FY2008 · HL · contact PI
Intravascular Delivery of AAV to Skeletal Muscle$525,284
P01 · FY2007 · HL · contact PI
AAV2-F.IX Hepatic Gene Transfer under Immunomodulation$362,364
R01 · FY2007 · HL · contact PI
Intravascular Delivery of AAV to Skeletal Muscle$504,619
P01 · FY2006 · HL · contact PI
AAV2-F.IX Hepatic Gene Transfer under Immunomodulation$380,350
R01 · FY2006 · HL · contact PI
Intravascular Delivery of AAV to Skeletal Muscle$458,346
P01 · FY2005 · HL
Efficacy and Safety of AAV Gene Transfer for Hemophilia$96,768
K01 · FY2004 · DK
Efficacy and Safety of AAV Gene Transfer for Hemophilia$96,768
K01 · FY2003 · DK
Efficacy and Safety of AAV Gene Transfer for Hemophilia$96,768
K01 · FY2002 · DK